Abstract
The development of an imaging probe targeting β-amyloid (Aβ) plaques in Alzheimer's disease labeled with technetium-99m, the most commonly used radioisotope for clinical diagnoses, has been strongly anticipated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have